PAWI-2

PAWI-2 is a p53-Activator and Wnt Inhibitor. PAWI-2 inhibits β3-KRAS signaling independent of KRAS. PAWI-2 selectively inhibits phosphorylation of TBK1. PAWI-2 activates apoptosis (activation of caspase-3/7), and induces PARP cleavage. PAWI-2 promotes optineurin translocation into the nucleus and causes G2/M arrest. PAWI-2 reverses cancer stemness and overcomes drug resistance in an integrin β3 KRAS-dependent human pancreatic cancer stem cells (hPCSCs) . PAWI-2 inhibits growth of tumors from hPCSCs in orthopic xenograft mice model[1][2].

Product Specifications

CAS Number

[1448427-02-8]

UNSPSC

12352005

Target

Apoptosis; Caspase; IKK; MDM-2/p53; Wnt

Type

Reference compound

Related Pathways

Apoptosis; NF-κB; Stem Cell/Wnt

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pawi-2.html

Purity

99.29

Smiles

O=C1N(C2=CC=C(S(=O)(N3CCN(C)C4=C3C=CC=C4)=O)C=C2)CCC1

Molecular Formula

C19H21N3O3S

Molecular Weight

371.45

References & Citations

[1]Cashman JR, et al. Effect of PAWI-2 on pancreatic cancer stem cell tumors. Invest New Drugs. 2024 May 25. |[2]Cheng J, et al. PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin β3-KRAS-dependent pancreatic cancer stem cells. Sci Rep. 2020 Jun 8;10 (1) :9162.